Mifepristone
|
|
Mifepristone 속성
- 녹는점
- 195-198°C
- 알파
- D20 +138.5° (c = 0.5 in chloroform)
- 끓는 점
- 544.13°C (rough estimate)
- 밀도
- 1.0731 (rough estimate)
- 굴절률
- 1.6290 (estimate)
- 저장 조건
- 2-8°C
- 용해도
- DMSO(최대 40mg/ml) 또는 에탄올(최대 20mg/ml)에 용해됩니다.
- 물리적 상태
- 노란색 고체
- 산도 계수 (pKa)
- 12.94±0.60(Predicted)
- 색상
- 노란색
- 수용성
- 474.8ug/L(22.5ºC)
- Merck
- 14,6186
- 안정성
- 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 3개월 동안 보관할 수 있습니다.
- InChIKey
- VKHAHZOOUSRJNA-GCNJZUOMSA-N
- CAS 데이터베이스
- 84371-65-3(CAS DataBase Reference)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | T | ||
---|---|---|---|
위험 카페고리 넘버 | 60-61 | ||
안전지침서 | 53-22-36/37/39-45 | ||
WGK 독일 | 3 | ||
RTECS 번호 | KG2955000 | ||
HS 번호 | 29372900 | ||
유해 물질 데이터 | 84371-65-3(Hazardous Substances Data) |
그림문자(GHS): | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Danger | ||||||||||||||
유해·위험 문구: |
|
||||||||||||||
예방조치문구: |
|
Mifepristone C화학적 특성, 용도, 생산
개요
Mifepristone is an orally-active progesterone and glucocorticoid receptor antagonist indicated for use as a post-coital contraceptive. In addition to being an abortifacient, mifepristone is reported to be effective in the treatment of ocular hypertension; its potential therapeutic effect in hormone-dependent tumors is currently under investigation.화학적 성질
Pale Yellow Solid용도
Mifepristone is a progesterone receptor antagonist with partial agonist activity. Abortifacient.Indications
Mifepristone is a progesterone receptor antagonist that has a high affinity for glucocorticoid receptors and little agonist effect.This drug has recently been approved for use in the United States for the treatment of hypercortisolism. At high doses, mifepristone blocks negative feedback of the hypothalamic–pituitary axis, thereby increasing endogenous corticotrophin and cortisol levels. Because mifepristone exerts its effects at the receptor level and not by altering glucocorticoid production, elevated serum cortisol and corticotrophin levels may not accurately reflect the effectiveness of the therapeutic regimen. Mifepristone does not inhibit cortisol binding to the mineralocorticoid receptor, so that the resulting corticotrophin disinhibition may cause potassium depletion. Thus, administration of a mineralocorticoid receptor antagonist such as spironolactone may be indicated with mifepristone. Hypoadrenalism, nausea, and drowsiness have been reported during prolonged administration of mifepristone.World Health Organization (WHO)
Mifepristone, an antiprogesterone used in combination with a prostaglandin for the termination of early pregnancy, was introduced in 1990. Use of the combination has been associated with episodes of coronary spasm that are attributed to administration of the prostaglandin and which have resulted in several cases of cardiac infarction and ventricular fibrillation. At least one of these incidents has been fatal.생물학적 활성
Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo . Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone.Pharmacokinetics
Following oral administration, mifepristone is rapidly absorbed, with a peak plasmaconcentration in approximately 90 minutes , an oral bioavailability of approximately 70%, and a term inal elimination half-life of 18 hours. It is 98% protein bound, primarily to album in and α1-acid glycoprotein. Mifepristone is metabolized primarily via CYP3A4 pathways involving mono- and di-N-demethylation and terminal hydroxylation of the 17-propynyl chain. The fact that approximately 83% of the drug is recovered in the feces and 9% in the urine suggests a biliary route of elimination. Mifepristone also demonstrates antiglucocorticoid activity.Clinical Use
An antiprogestin is a substance that competes with progesterone for its receptor and, ultimately, prevents progesterone from binding to and activating its receptor. Because progesterone is integral to the continuation of an early pregnancy, it is expected that antipro-gestins will interfere with pregnancy maintenance. In 1982, the first antiproges tin, mifepristone (RU 486), was reported. Mifepristone was shown to interrupt early stages of implantation and pregnancy in humans.참고 문헌
https://pubchem.ncbi.nlm.nih.gov/compound/mifepristone#section=Tophttps://www.drugbank.ca/drugs/DB00834
https://www.drugs.com/cdi/mifepristone-tablets.html
Mifepristone 준비 용품 및 원자재
원자재
준비 용품
Mifepristone 공급 업체
글로벌( 540)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Hebei Bonster Technology Co.,Limited | +8613315996897 |
bsterltd.wendy@gmail.com | China | 796 | 58 |
Shaanxi Dideu Medichem Co. Ltd | +86-29-81148696 +86-15536356810 |
1022@dideu.com | China | 3878 | 58 |
Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 |
sales1@chuanghaibio.com | China | 5895 | 58 |
Hong Kong Excellence Biotechnology Co., Ltd. | |
ada@sh-teruiop.com | China | 882 | 58 |
Wuhan Haorong Biotechnology Co.,ltd | +86-18565342920; +8618565342920 |
sales@chembj.net | China | 289 | 58 |
Nantong Guangyuan Chemicl Co,Ltd | +undefined17712220823 |
admin@guyunchem.com | China | 616 | 58 |
Shaanxi Franta Biotechnology Co., Ltd | +86-13082019107 +86-13082019107 |
admin@flanderff.com | China | 208 | 58 |
Sigma Audley | +86-15937194204 +86-18126314766 |
nova@sh-teruiop.com | China | 491 | 58 |
Hangzhou Hyper Chemicals Limited | +86-0086-57187702781 +8613675893055 |
info@hyper-chem.com | China | 295 | 58 |
Shaanxi TNJONE Pharmaceutical Co., Ltd | +8618092446649 |
sarah@tnjone.com | China | 1143 | 58 |
Mifepristone 관련 검색:
메트론이드아졸 레보노게스트렐 페닐히드라진
CHLOROPHOSPHONAZO III
PHENYL VALERATE
Misoprostol
Estr-9-en-3-one, 11-[4-(dimethylamino)phenyl]-5,17-dihydroxy-17-(1-propynyl)-, cyclic 1,2-ethanediyl acetal, (5a,11b,17b)-
Didemethyl Mifepristone,DIDESMETHYL MIFEPRISTONE,N-Didesmethyl Mifepristone
Mifepristone-d3
22-Hydroxy Mifepristone-d6
N-DESMETHYL MIFEPRISTONE,N-Demethyl Mifepristone
MIFEPRISTONE, [N-METHYL-3H]
HYDROXY MIFEPRISTONE,22-Hydroxy Mifepristone
Mifepristone
Toripristone
Mifepristone(RU486)
mifepristone methochloride
RU-486 (MIFEPRISTONE), [N-METHYL-3H]